A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)
The E-VITA study evaluated the efficacy and tolerability of two schedules of eribulin and lapatinib in patients with trastuzumab-pretreated HER-2-positive metastatic breast cancer. This multicenter, open-label phase II trial, randomly assigned patients with trastuzumab-pretreated HER-2-positive
metastatic breast cancer to lapatinib 1000 mg daily with eribulin 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate) days 1+8 every 21 days (split-dose arm) or eribulin 1.76 mg/m2 (equivalent to 2.0 mg/m2 eribulin
mesylate) day 1 every 21 days (3-weekly arm). Time to progression and tolerability were defined as primary end points; no sample size calculation for formal comparison of efficacy data has been performed. Secondary end points included objective response rate, clinical benefit rate, and overall
survival. Overall, 43 patients of a planned number of 80 patients were recruited. At a median follow-up of 28.7 months, the median time to progression was 8.1 months [95% confidence interval (CI): 4.8–9.4] in the split-dose arm and 6.5 months (95% CI: 4.6–13.4) in the 3-weekly
arm. Objective response rate was 52.4% (95% CI: 31.0–73.7) in the split-dose arm and 45.0% (95% CI: 23.2–66.8) in the 3-weekly arm, and clinical benefit rate was 71.4% (95% CI: 52.1–90.8) and 75.0% (95% CI: 56.0–94.0), respectively. Overall survival was also similar
in both arms. The most frequent grade 3–4 adverse events were neutropenia (58.5%) and leukopenia (39.0%). The combination of eribulin and lapatinib showed an acceptable safety profile with less toxicity observed in the eribulin 1.23 mg/m2 day 1+8 group. This might be
an alternative regimen when other treatment options are exhausted. Therefore, further clinical studies are warranted.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Women’s Hospital, Städtisches Klinikum Dessau
Women’s Hospital, Agaplesion Markus-Krankenhaus, Frankfurt am Main, Gynaecological Hospital, Charité Universitätsmedizin Berlin
University Women’s Hospital Kiel, UK-SH, Kiel
University Women’s Hospital Magdeburg, Otto-von Guericke-Universität, Magdeburg
University Women’s Hospital Würzburg
Breast Center, Diakovere Henriettenstiftung, Hannover
National Center for Tumor Diseases, University Hospital Heidelberg
German Breast Group, Neu-Isenburg
Women’s Hospital, University Hospital Tübingen
Women’s Hospital, UKE University Hospital Hamburg-Eppendorf KMTZ, Hamburg
Women’s Hospital, University Medical Center Mainz
Women’s Hospital, University Hospital Rostock
Women’s Hospital, Kliniken Essen Mitte Evang. Huyssens-Stiftung, Essen
Breast Center, St. Elisabeth Krankenhaus Hohenlind, Cologne
Women’s Hospital, Klinikum Chemnitz, Germany
Women’s Hospital, Agaplesion Markus-Krankenhaus, Frankfurt am Main
Publication date: April 1, 2019